Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia

Documenti analoghi

• Real‐World Outcomes in NPM1 ‐Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse
  di: Panagiotis Tsirigotis, et al.
  Pubblicazione: (2026)
• Acute Leukemias of Ambiguous Lineage With MDS‐Associated Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With MDS‐Associated Mutations: A Study From the Bone Marrow Pathology Group
  di: Timothy J. Kirtek, et al.
  Pubblicazione: (2024)
• Flow Cytometry‐Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non‐Intensive Chemotherapy
  di: Lukas H. Haaksma, et al.
  Pubblicazione: (2026)
• Level of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre‐Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients
  di: Ondrej Venglar, et al.
  Pubblicazione: (2025)
• Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1‐mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party
  di: Nour Moukalled, et al.
  Pubblicazione: (2024)